Cell-based assays have the potential to deliver more information about intracellular molecular targets than conventional methods such as molecular manipulation and random screening.
In an industry report published in September 2017, the global cell-based assay market is estimated at $3,625 million in 2016, and is anticipated to reach $10,618 million by 2023, registering a CAGR of 16.5% from 2017 to 2023.
Cell-based assays have the potential to deliver more information about intracellular molecular targets than conventional methods such as molecular manipulation and random screening. These assays are critical tools for studying cellular mechanisms in a biological context. A variety of cell-based assays are available in the market that cover applications such as cellular functions assessment, toxicity studies, and processes in biological research.
Rise in adoption of high-throughput screening methods and surge in preference of cell-based assays boost the market growth. In addition, increase in availability of funds for R&D and innovation, and increase in drug delivery activity supplement the growth further. However, high costs associated with equipment and standardization concerns in cell-based assay methods impede the market growth. Furthermore, increase in adoption of label-free cell-based assays and the untapped emerging countries offer lucrative opportunities for market development.
The global cell-based assay market is segmented based on product, application, end user, and geography. Based on product, it is divided into consumable, instrument, service, and software. The consumables segment is further classified into reagents, microplates, probes & labels, assay kits, cell lines, and others. Assay kit segment includes reporter gene assays, cell growth assays, second messenger assays, cell death assays, and others. The cell line segment is divided into immortalized cell lines, primary cell lines, and stem cell lines. Based on application, the market is categorized into drug discovery; basic research; absorption, distribution, metabolism, & excretion (ADME) studies; predictive toxicology; and others. On the basis of end user, it is categorized into pharmaceutical & biotechnology companies, academic & government research institutes, contract research organizations, and others. Geographically, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
The report provides a comprehensive analysis of the key players that operate in the global cell-based assay market.